Clinical Evidence for Rebound Hypercoagulability After Discontinuing Oral Anticoagulants for Venous Thromboembolism

David Keith Cundiff, MD


Medscape J Med. 2008;10(11):258 

In This Article


Increasing the duration of OAC treatment for VTE does not significantly reduce the overall adverse events. Rebound hypercoagulability accounts for about 2% of patients having recurrent VTE in the first 2 months after discontinuing OACs. RCTs evaluating the efficacy of OACs in VTE should include data for at least 2 months following OAC treatment. Trials of antithrombotic drug treatment for other indications should include data for appropriate time intervals after discontinuing the drugs.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.